Invitation to Participate in a Conference Call - Procyon to Discuss Interim Phase IIa Results for its Prostate Cancer Therapeutic, PCK3145
9/26/03
MONTREAL, Sep 26, 2003 (CNW Telbec via COMTEX) --
Procyon Biopharma Inc. (TSX: PBP) invites media representatives to participate in a conference call where the Company will discuss the interim Phase IIa results for its therapeutic for hormone-refractory prostate cancer, PCK3145. The conference call will be held on Monday, September 29, 2003, at 9:00 a.m (EST). A press release will be issued on Canada Newswire prior to the event.
During the conference call, Mr. Hans J. Mader, President and Chief Executive Officer of Procyon along with Dr. Chandra J. Panchal, Senior Executive Vice-President, Oncology and New Technologies, will present the new clinical data. The Principal Investigator of the study and other academic collaborators will also be available for comments.
To access the conference call, dial 1-800-814-4853 or 416-640-4127. Please connect approximately five minutes prior to the beginning of the call to ensure participation. To access the archived conference call, dial 1-800-289-8525 or 416-640-1917 and enter the reservation number 21019499(pound Key). The conference call will be archived for replay until December 29, 2003, at midnight.
About Procyon Biopharma
Procyon Biopharma Inc. is a publicly traded, Montreal-based, Canadian biotechnology company actively engaged in the discovery and development of innovative therapeutics and diagnostics in the fields of oncology and infectious diseases. Procyon brings its products and technologies from the laboratory to phase II human clinical trials and licenses them to larger pharmaceutical partners for further development and commercialization. Procyon's pipeline comprises a healthy combination of early-stage anti-cancer platforms, PSP(94) and ANsA, as well as anti-HIV/AIDS compounds, PL-100, a protease inhibitor, and PL-2500, a lead candidate integrase inhibitor. The Company also has two late-stage products: Fibrostat(R), licensed to Biovail Corporation, and Colopath(R)/ColorectAlert(TM), licensed to IMI International Medical Innovations Inc. Procyon shares are listed on the Toronto Stock Exchange (TSX) under the ticker symbol PBP. ( www.procyonbiopharma.com )
This release contains forward-looking statements that reflect the company's current expectation regarding future events. The forward- looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's filings. %SEDAR: 00010254EF |
